A Phase 2 interventional study of bevacizumab [Avastin] and cisplatin in Non-Squamous Non-Small Cell Lung Cancer, sponsored by Hoffmann-La Roche. Completed at 26 sites in Italy. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2015-10-08.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung — 9 open to participants now, 15 under way, 3 of them phase 3. Bevacizumab · Carcinoma, Non-Small-Cell Lung.
Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, this one is the 62nd largest by enrollment of the 149 interventional ones that give a count, is one of 9 that started in 2010, is one of 95 in phase 2, and was the 73rd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →9 of the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung are open now, in 3 countries. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–75
Mabscale, LLC · Sites in Russian Federation
Ages 18+
Hunan Province Tumor Hospital · Sites in China
Ages 18+
Anhui Provincial Cancer Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 70 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
150 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 105 · Phase 3 30 · Phase 4 2
First in 2001; this study’s year is marked. 9 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 86 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 56 across the 149 interventional studies. Of the 114 that completed or were terminated, 62 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 150 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche: 5 open now, 16 under way, 8 of them phase 3. Of 161 finished, 96 (60%) have results posted.
Among the 182 studies in Carcinoma, Non-Small-Cell Lung by Hoffmann-La Roche, this one is the 91st largest by enrollment of the 142 interventional ones that give a count, is one of 8 that started in 2010, is one of 56 in phase 2, and was the 41st registered.
Hoffmann-La Roche’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2001.
7 of the studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05654454Phase 3Mabscale, LLCA Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer | 2026-12 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT06683703Beijing Biostar Pharmaceuticals Co., Ltd.Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases | 2026-12-01 |
| NCT04227028City of Hope Medical CenterBrigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC | 2027-03-25 |
| NCT07453394Qilu Pharmaceutical Co., Ltd.QLS5132 Combination Therapy in Advanced Solid Tumors | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 150 studies testing bevacizumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 182 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This 2 arm study will evaluate the efficacy and safety of Avastin + gemcitabine, and Avastin + gemcitabine + attenuated doses of cisplatin, as first line treatment in elderly patients with non-squamous non-small cell lung cancer. Patients will be randomised to receive either Avastin 7.5mg/kg iv on day 1 + gemcitabine 1200mg/m2 on days 1-8 of each 3 week cycle, or Avastin 7.5mg/kg iv on day 1 + cisplatin 60mg/m2 on day 1 + gemcitabine 1000mg/m2 on days 1-8 of each 3 week cycle. After 6 cycles of combination therapy, all patients will continue to receive Avastin monotherapy. The anticipated time on study treatment is until disease progression, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: bevacizumab [Avastin] · Drug: gemcitabine
Drug: bevacizumab [Avastin] · Drug: cisplatin · Drug: gemcitabine
7.5mg/kg iv on day 1 of each 3 week cycle
60mg/m2 on day 1 of each 3 week cycle
1200mg/m2 on days 1-8 of each 3 week cycle
1000mg/m2 on days 1-8 of each 3 week cycle
Percentage of Participants Alive and Without Progressive Disease at Month 6
Disease progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (v 1.1). Disease progression was defined at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), progression of existing non-target lesions, or presence of new lesions.
Time frame: Month 6
Percentage of Participants With Disease Progression or Death
Disease progression was assessed according to RECIST criteria v1.1. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)
Progression Free Survival (PFS)
PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Disease progression was assessed according to RECIST criteria v 1.1. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.
Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death, or consent withdrawal (up to 53 months)
Percentage of Participants Alive at 12 Months After Randomization
Time frame: 1 year
Percentage of Participants Who Died
Time frame: From randomization to death or end of the study (up to 53 months)
Overall Survival (OS)
OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.
Time frame: From randomization to death or end of the study (up to 53 months)
Percentage of Participants by Best Overall Response
Best overall response was defined as the best response recorded from the start of the treatment until disease progression/recurrence, assessed according to RECIST criteria v 1.1. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to less than (\<) 10 millimeter (mm) in short axis; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions; Progressive Disease (PD): at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)
Percentage of Participants With an Objective Response
Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
Time frame: Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6
Percentage of Participants With Disease Control
Disease control was defined as having CR/PR/SD as per RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Time frame: Cycle 3 Day 15, Cycle 6 Day 15 and at Month 6
Duration of Response (DoR)
DoR was defined for participants who had achieved an objective response (CR/PR) (whichever status was recorded first) as the time period from first documentation of a response to the date of first occurrence of investigator documented disease progression or death. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as increase by at least 20% in the sum of the longest diameters of each target lesion, taking as a reference the smallest sum of the longest diameters or appearance of one or more new lesions. DoR was estimated using Kaplan Meier method.
Time frame: Baseline; Day 15 of Cycles 3 and 6; Month 6 and then every 3 months until disease progression, death or consent withdrawal (up to 53 months)
| Milestone | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Started | 44 | 42 |
| Completed | 8 | 6 |
| Not completed | 36 | 36 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Progressive disease (pd) | 0 | 1 |
| Withdrew: Death | 28 | 29 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Adverse event | 2 | 1 |
| Withdrew: Other | 4 | 2 |
Disease progression was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (v 1.1). Disease progression was defined at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), progression of existing non-target lesions, or presence of new lesions.
| percentage of participants | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Percentage of Participants Alive and Without Progressive Disease at Month 6 | 25.6 (12.5 to 38.6) | 30.0 (15.8 to 44.2) |
Disease progression was assessed according to RECIST criteria v1.1. Disease progression was defined as at least a 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
| percentage of participants | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Percentage of Participants With Disease Progression or Death | 86.0 | 90.0 |
PFS was defined as the interval between the date of randomization and the first documentation of progressive disease or death from any cause. Disease progression was assessed according to RECIST criteria v 1.1. Disease progression was defined at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated using Kaplan Meier method.
| months | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Progression Free Survival (PFS) | 4.33 (2.20 to 5.97) | 6.82 (4.49 to 8.52) |
| percentage of participants | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Percentage of Participants Alive at 12 Months After Randomization | 37.2 (22.8 to 51.7) | 47.5 (32.0 to 63.0) |
| percentage of participants | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Percentage of Participants Who Died | 69.8 | 72.5 |
OS was defined as the interval between the date of randomization and death from any cause. OS was estimated using Kaplan Meier method.
| months | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Overall Survival (OS) | 5.66 (3.38 to 13.0) | 12.0 (9.93 to 19.6) |
Best overall response was defined as the best response recorded from the start of the treatment until disease progression/recurrence, assessed according to RECIST criteria v 1.1. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to less than (\<) 10 millimeter (mm) in short axis; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesion, and no new lesions; Progressive Disease (PD): at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| percentage of participants | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| CR | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| PR | 14.0 (3.6 to 24.3) | 35.0 (20.2 to 49.8) |
| SD | 39.5 (24.9 to 54.1) | 37.5 (22.5 to 52.5) |
| PD | 16.3 (5.2 to 27.3) | 12.5 (2.2 to 22.7) |
| Not Assessable | 30.2 (16.5 to 44.0) | 15.0 (3.9 to 26.1) |
Objective response was defined as having a CR or PR according to a RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
| percentage of participants | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Cycle 3 | 11.6 (2.05 to 21.2) | 27.5 (13.7 to 41.3) |
| Cycle 6 | 9.3 (0.62 to 18.0) | 15.0 (3.93 to 26.1) |
| Month 6 | 4.7 (0.00 to 10.9) | 10.0 (0.70 to 19.3) |
Disease control was defined as having CR/PR/SD as per RECIST criteria v 1.1. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
| percentage of participants | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Cycle 3 | 53.5 (38.6 to 68.4) | 67.5 (53.0 to 82.0) |
| Cycle 6 | 27.9 (14.5 to 41.3) | 37.5 (22.5 to 52.5) |
| Month 6 | 25.6 (12.5 to 38.6) | 30.0 (15.8 to 44.2) |
DoR was defined for participants who had achieved an objective response (CR/PR) (whichever status was recorded first) as the time period from first documentation of a response to the date of first occurrence of investigator documented disease progression or death. CR was defined as disappearance of all target and non-target lesions and no new lesions, all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions. Disease progression was defined as increase by at least 20% in the sum of the longest diameters of each target lesion, taking as a reference the smallest sum of the longest diameters or appearance of one or more new lesions. DoR was estimated using Kaplan Meier method.
| months | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| Duration of Response (DoR) | 5.23 (3.93 to NA) | 5.97 (2.20 to 9.08) |
Collected over From baseline to 28 days after last dose of any study drug (up to 54 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bevacizumab + Gemcitabine | — | 17/43 (39.5%) | 38/43 (88.4%) |
| Bevacizumab + Gemcitabine + Cisplatin | — | 10/40 (25%) | 37/40 (92.5%) |
| Event | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| EmbolismVascular disorders | 1/43 | 2/40 |
| General physical health deteriorationGeneral disorders | 2/43 | 0/40 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/43 | 0/40 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/43 | 0/40 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/43 | 0/40 |
| Atrial fibrillationCardiac disorders | 0/43 | 1/40 |
| Myocardial infarctionCardiac disorders | 0/43 | 1/40 |
| NauseaGastrointestinal disorders | 0/43 | 1/40 |
| PneumoniaInfections and infestations | 0/43 | 1/40 |
| FallInjury, poisoning and procedural complications | 0/43 | 1/40 |
| Event | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 12/43 | 23/40 |
| NauseaGastrointestinal disorders | 8/43 | 17/40 |
| ThrombocytopeniaBlood and lymphatic system disorders | 5/43 | 16/40 |
| FatigueGeneral disorders | 8/43 | 15/40 |
| AnaemiaBlood and lymphatic system disorders | 5/43 | 12/40 |
| LeukopeniaBlood and lymphatic system disorders | 0/43 | 11/40 |
| HypertensionVascular disorders | 11/43 | 9/40 |
| AstheniaGeneral disorders | 9/43 | 10/40 |
| ConstipationGastrointestinal disorders | 3/43 | 8/40 |
| PyrexiaGeneral disorders | 8/43 | 8/40 |
All participants randomized set (RND) included all participants who provided informed consent and who were randomized to study medication.
| Age, Continuous(years) | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Mean | 74.2 ± 3.2 | 73.8 ± 3.5 | 74.0 ± 3.3 |
| Sex: Female, Male(Participants) | Bevacizumab + Gemcitabine | Bevacizumab + Gemcitabine + Cisplatin | Total |
|---|---|---|---|
| Female | 16 | 12 | 28 |
| Male | 28 | 30 | 58 |
The record gives a start of Feb 2010, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bevacizumab · Gemcitabine
Carcinoma, Non-Small-Cell Lung →